Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 13/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.42 |
| ▸ | MET | P08581 | 7/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571141 | 0.93 | GRIN2B (0.44) | GRIN2BGRIN1METNQO2 | |
| SCHEMBL23528659 | 0.93 | GRIN2B (0.44) | GRIN2BGRIN1METNQO2 | |
| SCHEMBL26527994 | 0.87 | MET (0.40) | GRIN2BGRIN1MET | |
| SCHEMBL26528009 | 0.86 | MET (0.42) | GRIN2BGRIN1MET | |
| SCHEMBL26527952 | 0.86 | PDE4A (0.40) | MET | |
| SCHEMBL26626478 | 0.81 | MET (0.47) | MET | |
| SCHEMBL26999015 | 0.81 | MET (0.51) | GRIN2BGRIN1METNQO2 | |
| SCHEMBL26626311 | 0.81 | TP53 (0.44) | MET | |
| SCHEMBL26626975 | 0.80 | MEN1 (0.45) | MET | |
| SCHEMBL26528428 | 0.80 | MET (0.42) | GRIN2BGRIN1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | GRIN2B 1553/4885GRIN1 728/4885MET 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.